Safoora Pordel1, Mahdi Sajedi Khanian2, Mohammad Hossein Karimi3, Hossein Nikoo4, Mehrnoosh Doroudchi1. 1. Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. 2. Department of Cardiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. 3. Fars Blood Transfusion Center, Shiraz, Iran. 4. Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract
BACKGROUND: IL-17A plays an important role in inflammatory responses in myocardial infarction (MI). IL-17A signals through its receptor, for which, Act1 (TRAF3IP2) functions as a key upstream adaptor in the pathway. AIM: To compare frequencies of functional polymorphisms of TRAF3IP2 (rs13210247, rs33980500) between patients with MI and healthy controls. METHODS: The selected SNPs were studied in 201 Iranian MI patients and 201 healthy blood donors from Fars Province by PCR-RFLP in association with clinicopathologic criteria of patients. CXCL1 plasma levels in 126 MI patients and 50 normal subjects were measured by ELISA. RESULTS: A significant increase in the mutant (T) allele of TRAF3IP2 rs33980500 in patients with diastolic dysfunction of the heart (P = .01) was observed. The highest correlation, however, was observed between the TRAF3IP2 rs33980500 TT genotype and T allele with left main coronary artery stenosis (P = .01, P < .001; OR = 31.03). T allele of TRAF3IP2 rs33980500 was also associated with female gender, family history of cardiovascular disease, and mechanical complications of heart (P = .04, P = .02, and P = .01, respectively). Moreover, TRAF3IP2 rs13210247 (G) correlated with mechanical complications of the heart (P = .01). A significant increase in the plasma levels of CXCL1 chemokine in patients (P = .0006) associated with TT genotype of TRAF3IP2 (rs33980500) was observed (P = .04). CONCLUSION: The gene variants of Act1 adaptor are associated with correlates of poor outcome in patients with MI and plasma CXCL1 levels.
BACKGROUND:IL-17A plays an important role in inflammatory responses in myocardial infarction (MI). IL-17A signals through its receptor, for which, Act1 (TRAF3IP2) functions as a key upstream adaptor in the pathway. AIM: To compare frequencies of functional polymorphisms of TRAF3IP2 (rs13210247, rs33980500) between patients with MI and healthy controls. METHODS: The selected SNPs were studied in 201 Iranian MI patients and 201 healthy blood donors from Fars Province by PCR-RFLP in association with clinicopathologic criteria of patients. CXCL1 plasma levels in 126 MI patients and 50 normal subjects were measured by ELISA. RESULTS: A significant increase in the mutant (T) allele of TRAF3IP2rs33980500 in patients with diastolic dysfunction of the heart (P = .01) was observed. The highest correlation, however, was observed between the TRAF3IP2rs33980500 TT genotype and T allele with left main coronary artery stenosis (P = .01, P < .001; OR = 31.03). T allele of TRAF3IP2rs33980500 was also associated with female gender, family history of cardiovascular disease, and mechanical complications of heart (P = .04, P = .02, and P = .01, respectively). Moreover, TRAF3IP2rs13210247 (G) correlated with mechanical complications of the heart (P = .01). A significant increase in the plasma levels of CXCL1 chemokine in patients (P = .0006) associated with TT genotype of TRAF3IP2 (rs33980500) was observed (P = .04). CONCLUSION: The gene variants of Act1 adaptor are associated with correlates of poor outcome in patients with MI and plasma CXCL1 levels.
Authors: Gilberto Vargas-Alarcón; Javier Angeles-Martínez; Teresa Villarreal-Molina; Edith Alvarez-León; Rosalinda Posadas-Sánchez; Guillermo Cardoso-Saldaña; Julian Ramírez-Bello; Nonanzit Pérez-Hernández; Juan Gabriel Juárez-Rojas; José Manuel Rodríguez-Pérez; José Manuel Fragoso; Carlos Posadas-Romero Journal: PLoS One Date: 2015-01-23 Impact factor: 3.240
Authors: Annayya R Aroor; Javad Habibi; Hemanth Kumar Kandikattu; Mona Garro-Kacher; Brady Barron; Dongqing Chen; Melvin R Hayden; Adam Whaley-Connell; Shawn B Bender; Thomas Klein; Jaume Padilla; James R Sowers; Bysani Chandrasekar; Vincent G DeMarco Journal: Cardiovasc Diabetol Date: 2017-05-05 Impact factor: 9.951